Pharmaceuticals
Pharma - Formulators
Revenue declined 6% YoY to INR 80.7bn, with US sales down 41% YoY mainly due to lower Lenalidomide sales. Management expects a stronger 2HFY27 with resumption of Semaglutide supplies.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
